Prognostic role of radiomics‐based body composition analysis for the 1‐year survival for hepatocellular carcinoma patients

Saalfeld, Sylvia; Kreher, Robert; Hille, Georg; Niemann, Uli; Hinnerichs, Mattes; Öcal, Osman; Schütte, Kerstin; Zech, Christoph J.; Loewe, Christian; van Delden, Otto; Vandecaveye, Vincent; Verslype, Chris; Gebauer, Bernhard; Sengel, Christian; Bargellini, Irene; Iezzi, Roberto; Berg, Thomas; Klümpen, Heinz J.; Benckert, Julia; Gasbarrini, Antonio; Amthauer, Holger; Sangro, Bruno; Malfertheiner, Peter; Preim, Bernhard; Ricke, Jens; Seidensticker, Max; Pech, Maciej; Surov, Alexey

doi:10.1002/jcsm.13315

Cited by 9 publications

(7 citation statements)

References 40 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2023, a study introduced radiomics-based body composition analysis in HCC patients treated with sorafenib plus SIRT, revealing that alterations in skeletal muscle mass and adipose tissue quality were associated with lower OS [98].…”

Section: Impact Of Sarcopenia On Radiotherapy Outcomesmentioning

confidence: 99%

The Negative Impact of Sarcopenia on Hepatocellular Carcinoma Treatment Outcomes

Cespiati,

Smith,

Lombardi

et al. 2024

Cancers

View full text Add to dashboard Cite

Introduction: Hepatocellular carcinoma (HCC) represents a major global health concern, characterized by evolving etiological patterns and a range of treatment options. Among various prognostic factors, sarcopenia, characterized by loss of skeletal muscle mass, strength, and function, has emerged as a pivotal contributor to HCC outcomes. Focusing on liver transplantation, surgical resection, locoregional treatments, and systemic therapies, this review aims to analyze the impact of sarcopenia on HCC treatment outcomes, shedding light on an underexplored subject in the pursuit of more personalized management. Methods: A comprehensive literature review was conducted by searching peer-reviewed articles on sarcopenia and treatment outcomes in patients with HCC from inception up to October 2023. Results: Sarcopenia was found to be prevalent among HCC patients, exhibiting different occurrence, possibly attributable to diverse diagnostic criteria. Notably, despite variations in studies utilizing skeletal muscle indices, sarcopenia independently correlated with lower overall survival (OS), recurrence-free survival (RFS), and progression-free survival (PFS) across surgical (both transplantation and resection), locoregional, and systemic therapies, including tyrosine-kinase inhibitors (TKIs) and immune-checkpoint inhibitors (ICIs). Moreover, a link between sarcopenia and increased rate and severity of adverse events, particularly in surgery and TKIs recipients, and larger tumor size at diagnosis was observed. While baseline sarcopenia negatively influenced treatment outcomes, alterations in muscle mass post-treatment emerged as primary determinants of reduced OS. Conclusions: Sarcopenia, either present before or after HCC treatment, negatively correlates with response to it, across all etiologies and therapeutic strategies. Although only a few studies have evaluated the impact of supervised physical activity training on muscle mass and OS after HCC treatment, it is crucial to evaluate the presence of sarcopenia before treatment initiation, to better stratify patients’ prognosis, thus performing a more tailored approach, and identify therapies able to restore muscle mass in HCC patients. Conversely, the impact of sarcopenia on HCC recurrence and extrahepatic spread remains inadequately explored.

show abstract

Section: Impact Of Sarcopenia On Radiotherapy Outcomesmentioning

confidence: 99%

The Negative Impact of Sarcopenia on Hepatocellular Carcinoma Treatment Outcomes

Cespiati,

Smith,

Lombardi

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Univariable In addition, individual publications were able to show that modern medical imaging post-processing methods, e. g., radiomics, also allow sensitive analysis of muscle quality [46,47]. The literature in this regard is based solely on individual studies.…”

Section: Diagnosismentioning

confidence: 99%

“…The literature in this regard is based solely on individual studies. Therefore, definitive population-based statements currently cannot be made [46,47].…”

Section: Diagnosismentioning

confidence: 99%

“…Einzelne Publikationen konnten darüber hinaus auch darstellen, dass die modernen post-processing-Verfahren der medizinischen Bildgebung wie z. B. Radiomics auch eine sensitive Analyse der Muskelqualität erlauben [46,47]. Die Literatur diesbezüglich basiert lediglich auf einzelnen Studien und kann bis dato daher keine populationsbasierten evidenten Aussagen treffen [46,47].…”

Section: Gesamtüberlebenunclassified

“…B. Radiomics auch eine sensitive Analyse der Muskelqualität erlauben [46,47]. Die Literatur diesbezüglich basiert lediglich auf einzelnen Studien und kann bis dato daher keine populationsbasierten evidenten Aussagen treffen [46,47].…”

Section: Gesamtüberlebenunclassified

See 2 more Smart Citations

Prognostic role of the skeletal musculature in oncology: significance, coherences and clinical implications

Surov,

Wienke,

Gutzmer

et al. 2023

Rofo

Self Cite

View full text Add to dashboard Cite

Background Sarcopenia is defined as a loss of muscle mass and strength as well as decreased physical performance. Method The present study provides a systematic overview of the current literature in regard to the prognostic role of sarcopenia in oncology. Conclusion In oncologic patients, sarcopenia occurs in 39.6 % of cases in a curative setting and in 49.2 % in a palliative setting. Sarcopenia is associated with dose-limiting toxicity. Furthermore, sarcopenia is associated with the occurrence of postoperative complications. Also, reduced muscle mass limits overall survival in most tumors both in a curative and a palliative setting. Therefore, analysis of the skeletal musculature on staging CT should be implemented in the clinical routine in oncology. Key Points: Citation Format

show abstract

Short‐term mortality prediction in acute pulmonary embolism: Radiomics values of skeletal muscle and intramuscular adipose tissue

Shahzadi,

Zwanenburg,

Frohwein

et al. 2024

J cachexia sarcopenia muscle

Self Cite

View full text Add to dashboard Cite

BackgroundAcute pulmonary embolism (APE) is a potentially life‐threatening disorder, emphasizing the importance of accurate risk stratification and survival prognosis. The exploration of imaging biomarkers that can reflect patient survival holds the potential to further enhance the stratification of APE patients, enabling personalized treatment and early intervention. Therefore, in this study, we develop computed tomography pulmonary angiography (CTPA) radiomic signatures for the prognosis of 7‐ and 30‐day all‐cause mortality in patients with APE.MethodsDiagnostic CTPA images from 829 patients with APE were collected. Two hundred thirty‐four features from each skeletal muscle (SM), intramuscular adipose tissue (IMAT) and both tissues combined (SM + IMAT) were calculated at the level of thoracic vertebra 12. Radiomic signatures were derived using 10 times repeated three‐fold cross‐validation on the training data for SM, IMAT and SM + IMAT for predicting 7‐ and 30‐day mortality independently. The performance of the radiomic signatures was then evaluated on held‐out test data and compared with the simplified pulmonary embolism severity index (sPESI) score, a well‐established biomarker for risk stratification in APE. Predictive accuracy was assessed by the area under the receiver operating characteristic curve (AUC) with a 95% confidence interval (CI), sensitivity and specificity.ResultsThe radiomic signatures based on IMAT and a combination of SM and IMAT (SM + IMAT) achieved moderate performance for the prediction of 30‐day mortality on test data (IMAT: AUC = 0.68, 95% CI [0.57–0.78], sensitivity = 0.57, specificity = 0.73; SM + IMAT: AUC = 0.70, 95% CI [0.60–0.79], sensitivity = 0.74, specificity = 0.54). Radiomic signatures developed for predicting 7‐day all‐cause mortality showed overall low performance. The clinical signature, that is, sPESI, achieved slightly better performance in terms of AUC on test data compared with the radiomic signatures for the prediction of both 7‐ and 30‐day mortality on the test data (7 days: AUC = 0.73, 95% CI [0.67–0.79], sensitivity = 0.92, specificity = 0.16; 30 days: AUC = 0.74, 95% CI [0.66–0.82], sensitivity = 0.97, specificity = 0.16).ConclusionsWe developed and tested radiomic signatures for predicting 7‐ and 30‐day all‐cause mortality in APE using a multicentric retrospective dataset. The present multicentre work shows that radiomics parameters extracted from SM and IMAT can predict 30‐day all‐cause mortality in patients with APE.

show abstract

Prognostic role of radiomics‐based body composition analysis for the 1‐year survival for hepatocellular carcinoma patients

Cited by 9 publications

References 40 publications

The Negative Impact of Sarcopenia on Hepatocellular Carcinoma Treatment Outcomes

The Negative Impact of Sarcopenia on Hepatocellular Carcinoma Treatment Outcomes

Prognostic role of the skeletal musculature in oncology: significance, coherences and clinical implications

Short‐term mortality prediction in acute pulmonary embolism: Radiomics values of skeletal muscle and intramuscular adipose tissue

Contact Info

Product

Resources

About